U.S. patent application number 14/877049 was filed with the patent office on 2016-01-28 for surface treating agent, filtering material for filter, and blood treatment filter.
This patent application is currently assigned to TERUMO KABUSHIKI KAISHA. The applicant listed for this patent is TERUMO KABUSHIKI KAISHA. Invention is credited to Shoji OCHIAI, Noboru TAGUCHI, Norifumi TOKUNAGA.
Application Number | 20160023148 14/877049 |
Document ID | / |
Family ID | 42827932 |
Filed Date | 2016-01-28 |
United States Patent
Application |
20160023148 |
Kind Code |
A1 |
OCHIAI; Shoji ; et
al. |
January 28, 2016 |
SURFACE TREATING AGENT, FILTERING MATERIAL FOR FILTER, AND BLOOD
TREATMENT FILTER
Abstract
A surface treating agent comprising a copolymer including: a
monomer (A) having a hydrophilic functional group of formula (2), a
monomer (B) having a basic functional group of formula (3) or (5),
and a monomer (C) having a reactive functional group of formula
(8), wherein the copolymer has a molar ratio of the monomer (A)/the
monomer (B)/and the monomer (C) between 87/10/3 and 98/1/1. In the
formulas, the R groups and n are defined. ##STR00001##
Inventors: |
OCHIAI; Shoji;
(Ashigarakami-gun, JP) ; TOKUNAGA; Norifumi;
(Ashigarakami-gun, JP) ; TAGUCHI; Noboru;
(Ashigarakami-gun, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
TERUMO KABUSHIKI KAISHA |
Tokyo |
|
JP |
|
|
Assignee: |
TERUMO KABUSHIKI KAISHA
Tokyo
JP
|
Family ID: |
42827932 |
Appl. No.: |
14/877049 |
Filed: |
October 7, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13259359 |
Sep 23, 2011 |
9186441 |
|
|
PCT/JP2010/054460 |
Mar 16, 2010 |
|
|
|
14877049 |
|
|
|
|
Current U.S.
Class: |
210/506 ;
524/555 |
Current CPC
Class: |
C08F 220/285 20200201;
C08F 220/28 20130101; B01D 29/00 20130101; C08F 220/26 20130101;
C08F 220/56 20130101; A61M 1/3633 20130101; C09D 133/10 20130101;
C09D 133/08 20130101; A61L 33/064 20130101 |
International
Class: |
B01D 39/16 20060101
B01D039/16; C09D 133/24 20060101 C09D133/24; C09D 133/14 20060101
C09D133/14 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 30, 2009 |
JP |
2009-083034 |
Claims
1. A surface treating agent fixed to a base material, wherein the
surface treating agent comprises a copolymer of monomer components
including: a monomer (A) having a hydrophilic functional group of
formula (2) below, a monomer (B) having a basic functional group of
formula (3) or (5) below, and a monomer (C) having a reactive
functional group of formula (8) below, wherein the copolymer has a
molar ratio of the monomer (A)/the monomer (B)/and the monomer (C)
being between 87/10/3 and 98/1/1, ##STR00008## wherein R.sup.1
represents a hydrogen atom or a methyl group, each of R.sup.3 and
R.sup.4 independently represents a hydrogen atom or an alkyl group
having 1 to 3 carbon atoms) ##STR00009## wherein each of R.sup.5s
represents a hydrogen atom or a methyl group, each of R.sup.6s
independently represents a hydrogen atom or an alkyl group having 1
to 4 carbon atoms, n represents an integer of 2 to 4, ##STR00010##
wherein R.sup.7 represents a hydrogen atom or a methyl group, n
represents an integer of 0 to 3, and Y represents a hydroxyl group,
an epoxy group, a primary amino group, a secondary amino group or a
hydrogen atom, and wherein the surface treating agent is fixed to
the base material by a chemical bonding between a reactive
functional group of the monomer (C) and a reactive functional group
of the base material.
2. The surface treating agent fixed to a base material according to
claim 1, wherein the monomer (A) of formula (2) is
N,N-dimethyl(meth)acrylamide.
3. The surface treating agent fixed to a base material according to
claim 1, wherein the monomer (B) of formula (3) is
N,N-dimethylaminoethyl(meth)acrylate,
N,N-diethylaminoethyl(meth)acrylate, or
N,N-diisopropylaminoethyl(meth)acrylate and the monomer of formula
(5) is N,N-dimetylaminopropyl(meth)acrylamide.
4. The surface treating agent fixed to a base material according to
claim 1, wherein the monomer (C) of formula (8) is
2-aminoethyl(meth)acrylamide.
5. A filtering material for filter, wherein at least a part of a
base material of the filtering material is coated with the surface
treating agent according to claim 1.
6. A blood treatment filter comprising: a housing having a blood
inlet port and a blood outlet port, and a filter unit which
partitions interior of the housing into a blood inlet chamber and a
blood outlet chamber, wherein at least a part of the filter unit is
made of the filtering material for filter according to claim 5.
Description
[0001] This application is a divisional of U.S. application Ser.
No. 13/259,359 filed on Sep. 23, 2011, which is a National Stage of
International Application No. PCT/JP2010/054460 filed on Mar. 16,
2010, and claims priority to Japanese Application No. 2009-083034
filed on Mar. 30, 2009, the entire contents of all three of which
is incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to a medical device,
particularly, a surface treating agent with which a blood contact
surface of a base material that is used for a blood treatment
filter is coated, a filtering material having the base material
coated with the surface treating agent and a blood treatment
filter.
DESCRIPTION OF THE RELATED ART
[0003] Recently, various polymer materials have been used for base
materials which are used for medical device. Polymer materials that
are foreign to organisms are in contact with blood while being
used, therefore, the base material is required to inhibit property
of adhesion and activation of platelets (antithrombotic
performance). To meet the requirement, the base material coated
with a certain surface treating agent on the surface is used in
general. Further, in a case where the base material is used for a
blood treatment filter as a medical device, the base material must
have an excellent blood filtration property (specifically,
leukocyte removal rate, platelet collection rate and the like).
[0004] Patent Literature 1 (described below) discloses a polymer
having a nonionic hydrophilic group and a nitrogen-containing basic
functional group as a surface treatment agent for blood treatment
filter, specifically, a copolymer of hydroxyethyl methacrylate and
diethylaminoethyl methacrylate. Patent Literature 1 discloses that
by coating a filtering material (a base material) with the
copolymer a leukocyte removal ratio and a platelet passage
(collection) ratio become higher.
[0005] Patent Literature 2 (described below) discloses a copolymer
including alkoxyalkyl methacrylate and a monomer having a basic
functional group (aminoalkyl methacrylates, aminoalkyl
methacrylamides or the derivatives thereof) as a surface treatment
agent for blood treatment filter. Patent Literature 2 discloses
that by covering a surface of a medical device (a base material)
with the copolymer, both the leukocyte removal ratio and the
platelet collection ratio become higher.
[0006] Patent Literature 3 (described below) discloses a cationic
material having a quaternary nitrogen on the main chain or side
chain as a surface treatment agent. Patent Literature 3 (described
below) discloses that by bonding a surface of a base material with
the cationic material, leukocyte removal ratio is improved.
PRIOR ART DOCUMENTS
Patent Literatures
[0007] Patent Literature 1: JP Hei 06-51060 B1 (1994)
(corresponding to U.S. Pat. No. 4,936,998 A)
[0008] Patent Literature 2: JP 2002-105136 A (corresponding to U.S.
Pat. No. 6,590,054 B2)
[0009] Patent Literature 3: JP 3379972 B2
SUMMARY OF INVENTION
Problem to be Solved by the Invention
[0010] However, the surface treating agent described in PATENT
LITERATURE 1 or 2 bonds weakly with the base material (fixes
insufficiently to the base material). Therefore, through
sterilizing or washing of the medical device, or contacting of the
medical device repeatedly with blood, the surface treating agent
tends to detach (elute) easily from the base material which causes
a problem that the antithrombotic performance is not maintained.
Further, leukocytes are adsorbed using the surface treating agent
described in PATENT LITERATURE 3. In spite of the improvement of
leukocyte removal rate, platelets are simultaneously adsorbed
(adhered) with leukocytes. Therefore, it causes a problem that the
platelet collection rate decreases. At the same time the adhered
platelets are activated which causes a problem that antithrombotic
level is insufficient.
[0011] The present invention has been created in view of the
above-mentioned problem. Herein, an object of the present invention
is to provide a surface treating agent. When a blood contact
surface of a base material that is used for a medical device is
coated with the surface treating agent, the surface treating agent
not only can fix the base material effectively and maintain an
excellent antithrombotic performance, but also can show excellent
leukocyte removal ability and excellent platelet collection rate
when a base material of a blood treatment filter is coated with the
surface treating agent. Another object of the present invention is
to provide a filtering material for filter coated with the surface
treating agent. Still another object of the present invention is to
provide a blood treatment filter.
Means for Solving the Problem
[0012] In order to solve the above-mentioned problem, a surface
treating agent of the present invention with which a blood contact
surface of a base material used for a medical device is coated is
characterized with
[0013] a copolymer of monomer components including:
[0014] a monomer (A) having a hydrophilic functional group of
formula (1) or (2) below,
[0015] a monomer (B) having a basic functional group and
[0016] a monomer (C) having a reactive functional group
[0017] as monomer components,
[0018] wherein the copolymer has a molar ratio of the monomer
(A)/(B)/(C) between 70/15/15 to 98/1/1.
##STR00002##
[0019] (wherein (R.sup.1)s represent hydrogen or a methyl group,
R.sup.2 represents an alkyl group having 1 to 4 carbon atoms, n
represents an integer of 2 to 4, and R.sup.3 and R.sup.4
independently represent hydrogen or an alkyl group having 1 to 3
carbon atoms respectively)
[0020] Preferably that the monomer (A) of formula (1) is
2-methoxyethyl (meth)acrylate or 2-ethoxyethyl (meth)acrylate
and/or the monomer (A) of formula (2) is N,N-dimethyl
(meth)acrylamide.
[0021] According to the above-mentioned particular structure,
making use of the copolymer that comprises a monomer (A), a monomer
(B) and a monomer (C) having a specified structure as monomer
components, wherein the copolymer has a specified molar ratio, the
monomer (A) inhibits the adhesion and activation of platelets.
Further, since the monomer (C) makes the surface treating agent
maintain to fix the base material, during the production and the
use, the surface treating agent is prevented from detaching
(eluting) from the base material. As a result, an inhibitive effect
of the adhesion and activation of platelets is maintained for a
long period of time. Further, when the surface treating agent is
applied to a blood treatment filter, the monomers (A) and (B) of
the surface treating agent simultaneously inhibit the adhesion and
activation of platelets and promote selective adsorption of
leukocyte.
[0022] A surface treating agent of the present invention is
inclusion of the copolymer, wherein the monomer (B) having a basic
functional group is at least one monomer selected from the monomers
of formulae (3), (4), (5) and (6) below, respectively.
##STR00003##
[0023] (wherein (R.sup.5)s represent hydrogen or a methyl group,
(R.sup.6)s independently represent hydrogen or an alkyl group
having 1 to 4 carbon atoms respectively, n represents an integer of
2 to 4, and (X.sup.-)s represent an anion derived from halogen,
sulfonic acid, sulfuric acid or the like)
[0024] It is preferred that the monomer (B) of formula (3) is
N,N-dimethylaminoethyl (meth)acrylate, N,N-diethylaminoethyl
(meth)acrylate, or N,N-diisopropylaminoethyl (meth)acrylate and/or
the monomer (B) of formula (5) is N,N-dimethylaminopropyl
(meth)acrylamide.
[0025] According to the above-mentioned construction, by
constructing the monomer (B) to have a specified structure, further
inhabitation of the adhesion and activation of platelets and
further selective adsorption of leukocytes are achieved at the same
time.
[0026] A surface treating agent of the present invention is
characterized with the copolymer, wherein the monomer (C) of the
copolymer having a reactive functional group is at least one
monomer selected from the monomers of formulae (7) and (8)
below.
##STR00004##
[0027] (wherein (R.sup.7)s represent hydrogen or a methyl group, n
represents an integer of 0 to 3, and (Y)s represent a hydroxyl
group, an epoxy group, a primary amine, secondary amine or
hydrogen)
[0028] It is preferred that the monomer (C) of formula (7) is
2-hydroxyethyl (meth)acrylate or glycidyl (meth)acrylate and/or the
monomer (C) of formula (8) is 2-aminoethyl (meth)acrylamide.
[0029] According to the above-mentioned construction, by
constructing the monomer (C) to have a specified structure, further
improvement of fixation of the surface treating agent to the base
material is achieved.
[0030] The filtering material for filter of the present invention
has a feature that at least a part of the base material is coated
with the surface treating agent. Further, it is preferred that the
surface treating agent is fixed by a chemical bonding between the
monomer (C) having a reactive functional group and a reactive
functional group of the base material.
[0031] According to the above-mentioned construction, by
constructing at least a part of the base material being coated with
the surface treating agent, an effect to inhibit the adhesion and
activation of platelets and an effect to adsorb leukocyte
selectively are given to the filtering material. Further, since the
filtering material (the base material) is maintained to be fixed
preferably by the chemical bonding, the surface treating agent is
prevented from detaching (eluting) from the filtering material (the
base material) during the production and the use of the filtering
material. As a result, the above-mentioned effects are
maintained.
[0032] The blood treatment filter of the present invention is
characterized with including: a housing having a blood inlet port
and a blood outlet port, and a filter unit which makes interior of
the housing separate into a blood inlet chamber and a blood outlet
chamber, wherein at least a part of the filter unit is used for the
filtering material mentioned above.
[0033] According to the above-mentioned construction, by
constructing at least a part of the filter unit being used for the
filtering material, an effect to inhibit the adhesion and
activation of platelets and an effect to adsorb leukocyte
selectively are given to the blood treatment filter. Further, since
the blood treatment filter (the filter unit) is maintained to be
fixed, during the production and the use of the blood treatment
filter, the surface treating agent is prevented from detaching
(eluting) from the filtering material for filter (the filter unit).
As a result, the above-mentioned effects are maintained.
Effect of the Invention
[0034] According to the surface treating agent of the present
invention, when a blood contact surface of a base material that is
used for a medical device is coated with the surface treating
agent, the surface treating agent not only can fix the base
material effectively and can maintain an excellent antithrombotic
performance, but also can show excellent leukocyte removal ability
and excellent platelet collection rate when a base material of a
blood treatment filter is coated with the surface treating agent.
Further, according to the filtering material for filter and the
blood treatment filter of the present invention, excellent
antithrombotic performance is maintained, and also excellent
leukocyte removal ratio and excellent platelet collection ratio are
shown.
BRIEF DESCRIPTION OF THE DRAWINGS
[0035] FIG. 1 is a cross sectional view showing a structure of the
blood treatment filter of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0036] Hereinafter, embodiments of the surface treating agent of
the present invention are described in detail. The surface treating
agent with which a blood contact surface of a base material used
for a medical device is coated comprising a copolymer of monomer
components including: a monomer (A) having a hydrophilic functional
group of formula (1) or (2) below, a monomer (B) having a basic
functional group and a monomer (C) having a reactive functional
group, wherein the copolymer has a molar ratio of the monomer
(A)/(B)/(C) between 70/15/15 to 98/1/1.
[0037] Since the copolymer has an appropriate molar ratio (a molar
ratio of the monomer (A)/(B)/(C) between 70/15/15 to 98/1/1), when
a blood contact surface of a base material that is used for a
medical device is coated with, the base material is fixed
effectively and an excellent antithrombotic performance can
maintained, and also excellent leukocyte removal ability and
excellent platelet collection rate can be shown when a base
material of a blood treatment filter is coated with. If the molar
ratio of the monomer (A) is below 70, the amount of the monomer (A)
is insufficient, therefore the adhesion and activation of platelets
cannot be inhibited, hence the antithrombotic performance may
decrease. While if a molar ratio of the monomer (A) is above 98,
the amount of the monomer (C) is insufficient, therefore the
copolymer cannot be fixed to the base material effectively.
##STR00005##
[0038] (wherein (R.sup.1)s represent hydrogen or a methyl group,
R.sup.2 represents an alkyl group having 1 to 4 carbon atoms, n
represents an integer of 2 to 4, and R.sup.3 and R.sup.4
independently represent hydrogen or an alkyl group having 1 to 3
carbon atoms respectively)
[0039] With respect to the monomer (A) which is a monomer component
of the copolymer (the surface treating agent), a hydrophilic
functional group is alkoxy group or amide group (unsubstituted
amide, N-1 substituted amide, N-2 substituted amide). Further, the
monomer (A) is represented by formula (1) or (2). The monomer (A)
has an effect to inhibit the adhesion and activation of
platelets.
[0040] The monomer (A) of the formula (1) described above includes
the alkoxyalkyl (meth)acrylates which include, for example,
methoxyethyl (meth)acrylate, methoxypropyl (meth)acrylate,
methoxybutyl (meth)acrylate, ethoxyethyl (meth)acrylate,
ethoxypropyl (meth)acrylate, ethoxybutyl (meth)acrylate,
propoxyethyl (meth)acrylate, propoxypropyl (meth)acrylate,
propoxybutyl (meth)acrylate, and the like. Each of them may be used
by itself or a plurality thereof may be used in combination. Among
the above monomers, from the viewpoints of economy and ease of
manipulation, methoxyethyl (meth)acrylate or ethoxyethyl
(meth)acrylate are preferred. 2-methoxyethyl (meth)acrylate or
2-ethoxyethyl (meth)acrylate are more preferred.
[0041] The monomer (A) of the formula (2) described above may be
(meth)acrylamides. Besides (meth)acrylamide, for example, N-methyl
(meth)acrylamide, N-ethyl (meth)acrylamide, N-propyl
(meth)acrylamide, N,N-dimethyl (meth)acrylamide, N,N-diethyl
(meth)acrylamide and N,N-dipropyl (meth)acrylamide. Each of them
may be used by itself or a plurality thereof may be used for the
monomer (A) in combination. Among the above monomers, from the
viewpoints of economy and ease of manipulation, N,N-dimethyl
(meth)acrylamide is preferred.
[0042] The monomer (B) having a basic functional group, which is a
monomer component of the copolymer, may be any monomer which can
copolymerize with the monomer (A) in a specific molar ratio.
Examples of the basic functional group include amino groups
(primary amines, secondary amines, tertiary amines, quaternary
amines (ammonium salts)), a pyridyl group, an aziridine group and
an imidazolyl group. The monomer (B) has an effect to adsorb
leukocyte selectively.
[0043] It is preferred that the monomer (B) is at least one monomer
selected from the monomers of formulae (3), (4), (5) and (6) below,
respectively.
##STR00006##
[0044] (wherein (R.sup.5)s represent hydrogen or a methyl group,
(R.sup.6)s independently represent hydrogen or an alkyl group
having 1 to 4 carbon atoms respectively, n represents an integer of
2 to 4, and (X.sup.-)s represent an anion derived from halogen,
sulfonic acid, sulfuric acid or the like)
[0045] The monomer (B) of the formula (3) above may be aminoalkyl
(meth)acrylates. Examples thereof include, for example, aminoethyl
(meth)acrylate, aminoisopropyl (meth)acrylate, amino-n-butyl
(meth)acrylate, N-methylaminoethyl (meth)acrylate,
N-ethylaminoisobutyl (meth)acrylate, N-isopropylaminoethyl
(meth)acrylate, N-n-butylaminoethyl (meth)acrylate,
N-t-butylaminoethyl (meth)acrylate, N,N-dimethylaminoethyl
(meth)acrylate, N,N-dimethylaminopropyl (meth)acrylate,
N,N-dimethylaminobutyl (meth)acrylate, N-methyl-N-ethylaminoethyl
(meth)acrylate, N-methyl-N-butylaminoethyl (meth)acrylate,
N,N-diethylaminoethyl (meth)acrylate, N,N-diethylaminopropyl
(meth)acrylate, N,N-diprop ylaminoethyl (meth)acrylate,
N,N-dipropylaminopropyl (meth)acrylate and N,N-diaminobutylpropyl
(meth)acrylate. Each of them may be used by itself or a plurality
thereof may be used in combination. Among the above monomers, from
the viewpoints of economy and ease of manipulation,
N,N-dimethylaminoethyl (meth)acrylate, N,N-diethylaminoethyl
(meth)acrylate or N,N-diisopropylaminoethyl (meth)acrylate are
preferred.
[0046] The monomer of the formula (5) above may be aminoalkyl
(meth)acrylamides. Examples thereof include, for example,
aminoethyl (meth)acrylamide, aminoisopropyl (meth)acrylamide,
amino-n-butyl (meth)acrylamide, N-methylaminoethyl
(meth)acrylamide, N-ethylaminoisobutyl (meth)acrylamide,
N-isopropylaminomethyl (meth)acrylamide, N-n-butylaminoethyl
(meth)acrylamide, N-t-butylaminoethyl (meth)acrylamide,
N,N-dimethylaminoethyl (meth)acrylamide, N,N-dimethylaminopropyl
(meth)acrylamide, N,N-dimethylaminobutyl (meth)acrylamide,
N-methyl-N-ethylaminoethyl (meth)acrylamide,
N-methyl-N-butylaminoethyl (meth)acrylamide, N,N-diethylaminoethyl
(meth)acrylamide, N,N-diethylaminopropyl (meth)acrylamide,
N,N-dipropylaminoethyl (meth)acrylamide, N,N-dipropylaminopropyl
(meth)acrylamide and N,N-diaminobutylpropyl (meth)acrylamide. Each
of them may be used by itself or a plurality thereof may be used in
combination. Among the above monomers, from the viewpoints of
economy and ease of manipulation, N,N-dimethylaminopropyl
(meth)acrylamide is preferred.
[0047] The monomers (B) of the formulae (4) and (6) above are each
derivatives obtained by treating the monomers of the formulae (3)
and (5) above respectively, with an alkyl halide, an alkyl sulfate
or the like to convert them into quaternary ammonium salts.
[0048] Further, with respect to the present invention, the monomers
(B), except the formulae (3) to (6) above, may include at least one
monomer selected from the group consisting of aminostyrene,
N,N-dimethylaminostyrene, N,N-diethylaminostyrene, vinylpyridine,
N-methylvinylpyridine, N-ethylvinylpyridine, vinylquinoline,
ethyleneimine, propyleneimine, N-aminoethylethyleneimine,
vinylimidazole, vinylpyrazoline and vinylpyrazine. Furthermore, the
monomers may be each derivatives obtained by treating the monomers
described above respectively with an alkyl halide, an alkyl sulfate
or the like to convert them into quaternary ammonium salts.
[0049] The monomer (C) having a reactive functional group is a
monomer component of the copolymer, whatever monomer having a
reactive functional group that is capable to copolymerize with the
monomer (A) and (B) in a specific molar ratio may be used for a
monomer component of the copolymer. The reactive functional group
includes, for example, a hydroxyl group, an epoxy group, a primary
amine, secondary amine or hydrogen. The monomer (C) has an effect
to fix the copolymer (the surface treating agent) to the base
material.
[0050] It is preferred that the monomer (C) is at least one monomer
selected from the monomers of formulae (7) and (8) below.
##STR00007##
[0051] (wherein (R.sup.7)s represent hydrogen or a methyl group, n
represents an integer of 0 to 3, and (Y)s represent a hydroxyl
group, an epoxy group, a primary amine, secondary amine or
hydrogen)
[0052] The monomer (C) of the formula (7) above may be any of, for
example, hydroxyalkyl (meth)acrylate, epoxyalkyl (meth)acrylate,
aminoalkyl (meth)acrylate and (meth)acrylic acid. Each of them may
be used by itself or a plurality thereof may be used in
combination. Among the above monomers, from the viewpoints of
economy and ease of manipulation, hydroxyalkyl (meth)acrylate or
epoxyalkyl (meth)acrylate are preferred. Hydroxyethyl
(meth)acrylate (2-hydroxyethyl (meth)acrylate) or glycidyl
(meth)acrylate are more preferred.
[0053] The monomer (C) of the formula (8) above may be any of, for
example, hydroxyalkyl (meth)acrylamide, epoxyalkyl
(meth)acrylamide, aminoalkyl (meth)acrylamide, (meth)acrylamide.
Each of them may be used by itself or a plurality thereof may be
used in combination. Among the above monomers, from the viewpoints
of economy and ease of manipulation, aminoalkyl (meth)acrylamide is
preferred. Aminoethyl (meth)acrylamide (2-aminoethyl
(meth)acrylamide) is more preferred.
[0054] The copolymer has preferable a mass-average molecular weight
of 3,000 to 300,000 and more preferably 7,000 to 50,000. If the
mass-average molecular weight is less than 3,000, it is often
difficult to synthesize the copolymer. On the other hand, if the
mass-average molecular weight is more than 300,000, it is often
difficult to dissolve the copolymer into organic solvents to coat
(coating) the base material. Due to this, fixation of the copolymer
to the base material tends to become difficult.
[0055] The medical device used for the present invention means a
blood contact surface. Examples of the medical device include a
blood treatment filter, a plasma separator, a blood bag, a blood
circuit, an indwelling needle, an oxygenator, a blood reservoir, a
dialyzer, a catheter, a guide wire, a stent, an artificial blood
vessel, a coalescence preventing material, a wound covering
material, and the like. The surface treating agent (the copolymer)
of the present invention is preferably used for a blood treatment
filter, specifically, for a filtering material that is used for a
blood treatment filter (a leukocyte removing filter of platelet
passage-type).
[0056] Hereinafter, the filtering material of the present invention
will be described. The filtering material has a feature to have a
base material at least a part of which or a blood contact portion
therein is coated with the surface treating agent mentioned
above.
[0057] The base material may be in the form of a sponge-like porous
material (a three dimensionally networked continuously porous
material), a nonwoven fabric, a woven fabric, a knitted fabric and
the like. Among them, a sponge-like porous material or a nonwoven
fabric is preferred. In the case of a sponge-like porous material,
a mean pore diameter measured using a perm porosimeter of 1 to 20
.mu.m is preferred. If the mean pore diameter is below 1 .mu.m, the
filter material tends to be clogged while if it is above 20 .mu.m,
the performance (the removal ratio of leukocyte) as the filtering
material for filter (blood treatment filter) may sometimes
decrease.
[0058] The material of the base material may be, for example, any
of synthetic polymers such as polyester (polyethylene
terephthalate, polybutylene terephthalate), polyolefin, halogenated
polyolefin, polyurethane, polyamide, polysulfone, polyethersulfone,
and mixtures thereof.
[0059] The method for coating the base material with the surface
treating agent includes such known methods as a coating method; a
method using graft polymerization with radiation, electron beam or
ultraviolet ray; and a method using a chemical reaction with a
functional group of the base material.
[0060] As the filtering material has the base material coated with
the surface treating agent, it is preferable that the surface
treating agent on the base material is fixed by a chemical bonding
between a monomer (C) of the surface treating agent and a reactive
functional group of the base material. The functional group of the
base material includes an epoxy group, a carboxy group, a hydroxyl
group and the like. Further, a base material itself which has the
reactive functional group may be selected, or the reactive
functional group may be introduced into a base material using such
as graft polymerization.
[0061] Hereinafter, the blood treatment filter of the present
invention will be described in detail. As shown in FIG. 1, the
blood treatment filter 1 includes: a housing 2 having a blood inlet
port 4 and a blood outlet port 6, and a filter unit 7 which
disposes to separate the inner space of the housing 2 separate into
a blood inlet chamber 8 and a blood outlet chamber 9, wherein at
least a part of the filter unit is used for the filtering material
mentioned above.
[0062] The housing 2 includes: a cover 3 having one end where a
blood inlet port 4 is formed, through which blood is introduced is
formed; and a bottom 5 having one end is made to flow out, where a
blood outlet port 6 through which the blood treated by the filter
unit 7. A periphery of the filter unit 7 is sandwiched between the
cover 3 and the bottom 5. Hereon, the contact portions are
fusion-bonded by high frequency fusion or ultrasonic fusion.
Thereby, the inner space of the housing 2 is separated into the
blood inlet chamber 8 communicating with the blood inlet port 4 and
the blood outlet chamber 9 communicating with the blood outlet port
6. Further, the material of the housing 2 may be, for example, any
of polycarbonate, polyvinyl chloride, ethylene-vinyl acetate
copolymer, ABS resin, polyolefin and the like.
[0063] The blood treatment filter 1 has such a structure that the
introduced blood flows from the blood inlet port 4 into the housing
2, then via the blood inlet chamber 8, passes through the filter
unit 7, flows into the blood outlet chamber 9 and finally flows out
of the housing 2 from the blood outlet port 6.
[0064] The filter unit 7 includes a main filter unit 7b and a
pre-filter unit 7a which is attached on the up-stream side of the
main filter unit 7b. The main filter unit 7b removes leukocytes
from the introduced blood. The pre-filter unit 7a has a larger mean
pore diameter than the main filter unit 7b. Incoming blood easily
enters the pre-filter unit 7a before the main filter unit 7b, and
the pre-filter unit 7a hardly removes leukocytes. In addition,
aggregates could be formed in the blood by aggregation of proteins
and blood components. Therefore, pre-filer unit 7a also has a role
to remove the aggregates to inhibit or to prevent the aggregates
from clogging the main filter unit 7b.
[0065] At least a part of the filter unit 7 being made of the
filtering material mentioned above means specifically that the
copolymer (the surface treating agent) coats (fixes) only the main
filter unit 7b. Preferably, the main filter unit 7b has a
multi-layer structure to improve leukocyte removal ability.
[0066] When the main filter unit 7b is made of such a base material
as a sponge-like porous membrane of polyurethane, this base
material functions as a filtering material. The base material is
capable of capturing leukocyte selectively (leukocyte removal
property) and passing platelet and erythrocyte (platelet collection
property and erythrocyte collection property). In this case, it is
preferred that only a downstream layer of the main filter unit 7b
is coated (fixed) with the copolymer (the surface treating agent),
thus an capability to capture leukocyte selectively is added to the
downstream layer in order to improve the leukocyte removal property
of the downstream layer better than that of the upstream layer, and
to maintain the ability to pass platelet and erythrocyte. Then, it
is possible to obtain the same effect with a smaller number of the
stacked treated base material layers than a larger number of the
untreated base material layers. Thereby, the smaller number of the
layer reduces the residual platelet and erythrocyte in the base
material. Therefore, it is possible to improve a platelet
collection rate and an erythrocyte collection rate.
[0067] If the main filter unit 7b is made of a base material, for
example, such as a nonwoven fabric of polyester, which itself has
its own ability to capture leukocyte and platelet (leukocyte
removal property), and, the ability to pass erythrocyte
(erythrocyte collection property), it is preferred that all layers
of the main filter unit 7b is coated (fixed) with the copolymer
(the surface treating agent). Thereby, an ability to pass platelet
is added, and, an ability to capture leukocyte is to be maintained
or improved.
[0068] Further, with respect to the main filter unit 7b, the amount
of fixed copolymer (the surface treating agent) on the main filter
unit 7b may be increased toward downstream side (along with the
blood flow direction).
[0069] Further, in the present invention, the configuration of the
filter unit 7 is not limited to the combination of the main filter
unit 7b and pre-filter 7a. The configuration made of the main
filter unit 7b alone may satisfy the present invention.
[0070] The blood treatment filter 1 (the filter unit 7) removes
leukocytes selectively from the blood (such as the whole blood)
flowing therethrough and passes platelets, erythrocytes and plasma.
Therefore, a blood bag system equipped with the blood treatment
filter 1 collects the blood free of leukocytes. Moreover, a blood
product free of leukocytes is produced by separating each of blood
cell components that is separated from the filtered blood which
causes little or no side effect due to leukocytes.
EXAMPLES
[0071] Hereinafter, the present invention will be described in
detail by examples. However, the present invention is not limited
thereto. Examples 1 to 8 and Comparative Examples 1 to 5 relate to
preparation of surface treating agents. Test Examples 1 to 7 relate
to evaluation of performances (amount of fixation, blood filtration
property and antithrombotic performance) of surface treating
agents.
(1) Preparation of the Surface Treating Agents
Example 1
[0072] 32.7 g of 2-methoxyethyl acrylate (MEA; produced by Wako
Pure Chemical Industries, Ltd.), 2.2 g of N,N-dimethyaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 1.8 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 145.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 37 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
dispensed into the solution by stifling, then, the solution was
dispensed by drops into n-hexane (produced by Kokusan Chemical Co.,
Ltd.) to form precipitates and the product was isolated. The
isolated product was dissolved in acetone and the resulting
solution was added dropwise to n-hexane to form precipitates and
thus purified totally three times. The purified product was dried
under reduced pressure over a whole day to obtain a surface
treating agent. The composition (molar ratio of monomer components)
of the obtained polymer was determined by .sup.1H-NMR. The molar
ratio of monomers was MEA/DMAEMA/HEMA=90/5/5. The mass average
molecular weight was 32,000.
Example 2
[0073] 28.7 g of N,N-dimethyl acrylamide (DMAA; produced by Wako
Pure Chemical Industries, Ltd.), 1.5 g of N,N-dimethyaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 2.0 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 140.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 34 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
dispensed into the solution by stifling, then, the solution was
added dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.)
to form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under a reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was DMAA/DMAEMA/HEMA=92/3/5. The mass average molecular weight was
44,000.
Example 3
[0074] 39.0 g of 2-methoxyethyl acrylate (MEA; produced by Wako
Pure Chemical Industries, Ltd.), 0.6 g of N,N-diethyaminoethyl
methacrylate (DEAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 0.4 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 160.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 40 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
dispensed into the solution by stifling, then, the solution was
added dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.)
to form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was MEA/DEAEMA/HEMA=98/1/1. The mass average molecular weight was
38,000.
Example 4
[0075] 15.0 g of N,N-dimethyl acrylamide (DMAA; produced by Wako
Pure Chemical Industries, Ltd.), 5.5 g of N,N-dimethyaminopropyl
methacrylamide (DMAPMAm; produced by Wako Pure Chemical Industries,
Ltd.) and 4.2 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 100.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 25 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
80 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
dispensed into the solution by stifling, then, the solution was
added dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.)
to form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was DMAA/DMAPMAm/HEMA=70/15/15. The mass average molecular weight
was 28,000.
Example 5
[0076] 23.0 g of 2-ethoxyethyl methacrylate (EEMA; produced by Wako
Pure Chemical Industries, Ltd.), 3.6 g of N,N-dimethylaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 3.3 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 120.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 30 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
added with stirring to the solution, then, the solution was added
dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.) to
form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was EEMA/DMAEMA/HEMA=76/12/12. The mass average molecular weight
was 18,000.
Example 6
[0077] 27.0 g of 2-methoxyethyl acrylate (MEA; produced by Wako
Pure Chemical Industries, Ltd.), 5.0 g of N,N-diisopropylaminoethyl
methacrylate (DiPAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 1.0 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 130.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 33 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
added with stirring to the solution, then, the solution was added
dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.) to
form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was MEA/DiPAEMA/HEMA=87/10/3. The mass average molecular weight was
27,000.
Example 7
Synthesis of 2-aminoethyl acrylamide (AEAAm) hydrochloride
[0078] 5.0 g of N-(t-butoxycarbonyl)-1,2-diaminoethane (produced by
Tokyo Chemical Industry Co., Ltd.) was dissolved in 100 mL of
anhydrous chloroform (produced by Wako Pure Chemical Industries
Ltd.), and 5.0 g of triethylamine (produced by Wako Pure Chemical
Industries Ltd.) was added to the solution. With the solution kept
cooled in an ice bath, 2.5 g of acryloyl chloride (produced by Wako
Pure Chemical Industries Ltd.) was added dropwise to the solution
with stirring. After the addition, stifling was kept for another 30
minutes, then the chloroform layer was rinsed with 20 mL.times.3
times of 1 N hydrochloric acid and further with 20 mL.times.3 times
of saturated sodium bicarbonate aqueous solution. Then, the
chloroform layer was desiccated over anhydrous sodium sulfate, and
was evaporated to dryness. Subsequently after the removal of the
N-(t-butoxycarbonyl) protective group with 2.5 mL of 37 mass %
hydrochloric acid, the residue was freeze-dried. The obtained
product was determined by .sup.1H-NMR. The product was found to be
2-aminoethyl acrylamide hydrochloride, and the yield was 3.2 g
(77%)
[0079] Synthesis of Polymer Having 2-Aminoethyl Acrylamide (AEAAm)
as a Reactive Functional Group
[0080] 25.0 g of 2-methoxyethyl acrylate (MEA; produced by Wako
Pure Chemical Industries, Ltd.), 1.5 g of N,N-dimethyaminoethyl
acrylate (DMAEA; produced by Wako Pure Chemical Industries, Ltd.)
and 1.6 g of 2-aminoethyl acrylamide (AEAAm) chloride synthesized
above were dissolved in 110.0 g of anhydrous dimethylformamide
(DMF; produced by Wako Pure Chemical Industries Ltd.). After having
nitrogen flow in this solution for 1 hour, 1 mL of DMF solution of
28 mg of 2,2'-azobisisobutyronitrile (AIBIN; produced by Wako Pure
Chemical Industries, Ltd.) was added to the solution, and the
solution was allowed to polymerize at 80.degree. C. for 8 hours.
After completion of the polymerization, 80 mL of acetone (produced
by Kokusan Chemical Co., Ltd.) was added with stirring to the
solution, then, the solution was added dropwise to n-hexane
(produced by Kokusan Chemical Co., Ltd.) to form precipitates and
the product was isolated. The isolated product was dissolved in
acetone and the resulting solution was added dropwise to n-hexane
to form precipitates and thus purified totally three times. The
purified product was dried under reduced pressure over a whole day
to obtain a surface treating agent. The composition (molar ratio of
monomer components) of the obtained polymer was determined by
.sup.1H-NMR. The molar ratio of monomers was
MEA/DMAEA/AEAAm=90/5/5. The mass average molecular weight was
26,000.
Example 8
[0081] 22.0 g of N,N-dimethyl acrylamide (DMAA; produced by Wako
Pure Chemical Industries, Ltd.), 2.0 g of N,N-dimethyaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 1.8 g of glycidyl methacrylate (GMA; produced by Wako
Pure Chemical Industries, Ltd.) were dissolved in 100.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 26 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
added with stifling to the solution, then, the solution was added
dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.) to
form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was DMAA/DMAEMA/GMA=90/5/5. The mass average molecular weight was
41,000.
Comparative Example 1
[0082] 31.0 g of 2-methoxyethyl acrylate (MEA; produced by Wako
Pure Chemical Industries, Ltd.), 2.0 g of N,N-dimethyaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and were dissolved in 130.0 g of anhydrous dimethylformamide
(DMF; produced by Wako Pure Chemical Industries Ltd.). After having
nitrogen flow in this solution for 1 hour, 1 mL of DMF solution of
34 mg of 2,2'-azobisisobutyronitrile (AIBIN; produced by Wako Pure
Chemical Industries, Ltd.) was added to the solution, and the
solution was allowed to polymerize at 80.degree. C. for 8 hours.
After completion of the polymerization, 100 mL of acetone (produced
by Kokusan Chemical Co., Ltd.) was added with stirring to the
solution, then, the solution was added dropwise to n-hexane
(produced by Kokusan Chemical Co., Ltd.) to form precipitates and
the product was isolated. The isolated product was dissolved in
acetone and the resulting solution was added dropwise to n-hexane
to form precipitates and thus purified totally three times. The
purified product was dried under reduced pressure over a whole day
to obtain a surface treating agent. The composition (molar ratio of
monomer components) of the obtained polymer was determined by
.sup.1H-NMR. The molar ratio of monomers was MEA/DMAEMA=95/5. The
mass average molecular weight was 52,000.
Comparative Example 2
[0083] 30.0 g of N,N-dimethyl acrylamide (DMAA; produced by Wako
Pure Chemical Industries, Ltd.), 2.5 g of N,N-dimethyaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and were dissolved in 130.0 g of anhydrous dimethylformamide
(DMF; produced by Wako Pure Chemical Industries Ltd.). After having
nitrogen flow in this solution for 1 hour, 1 mL of DMF solution of
33 mg of 2,2'-azobisisobutyronitrile (AIBIN; produced by Wako Pure
Chemical Industries, Ltd.) was added to the solution, and the
solution was allowed to polymerize at 80.degree. C. for 8 hours.
After completion of the polymerization, 100 mL of acetone (produced
by Kokusan Chemical Co., Ltd.) was added with stirring to the
solution, then, the solution was added dropwise to n-hexane
(produced by Kokusan Chemical Co., Ltd.) to form precipitates and
the product was isolated. The isolated product was dissolved in
acetone and the resulting solution was added dropwise to n-hexane
to form precipitates and thus purified totally three times. The
purified product was dried under reduced pressure over a whole day
to obtain a surface treating agent. The composition (molar ratio of
monomer components) of the obtained polymer was determined by
.sup.1H-NMR. The molar ratio of monomers was DMAA/DMAEMA=95/5. The
mass average molecular weight was 49,000.
Comparative Example 3
[0084] 30.0 g of 2-methoxyethyl acrylate (MEA; produced by Wako
Pure Chemical Industries, Ltd.) and 1.5 g of 2-hydroxyethyl
methacrylate (HEMA; produced by Wako Pure Chemical Industries,
Ltd.) were dissolved in 125.0 g of anhydrous dimethylformamide
(DMF; produced by Wako Pure Chemical Industries Ltd.). After having
nitrogen flow in this solution for 1 hour, 1 mL of DMF solution of
32 mg of 2,2'-azobisisobutyronitrile (AIBIN; produced by Wako Pure
Chemical Industries, Ltd.) was added to the solution, and the
solution was allowed to polymerize at 80.degree. C. for 8 hours.
After completion of the polymerization, 100 mL of acetone (produced
by Kokusan Chemical Co., Ltd.) was added with stifling to the
solution, then, the solution was added dropwise to n-hexane
(produced by Kokusan Chemical Co., Ltd.) to form precipitates and
the product was isolated. The isolated product was dissolved in
acetone and the resulting solution was added dropwise to n-hexane
to form precipitates and thus purified totally three times. The
purified product was dried under reduced pressure over a whole day
to obtain a surface treating agent. The composition (molar ratio of
monomer components) of the obtained polymer was determined by
.sup.1H-NMR. The molar ratio of monomers was MEA/HEMA=95/5. The
mass average molecular weight was 77,000.
Comparative Example 4
[0085] 20.0 g of N,N-dimethyl acrylamide (DMAA; produced by Wako
Pure Chemical Industries, Ltd.), 13.0 g of N,N-dimethyaminoethyl
methacrylate (DMAEMA; produced by Wako Pure Chemical Industries,
Ltd.) and 2.0 g of 2-hydroxyethyl methacrylate (HEMA; produced by
Wako Pure Chemical Industries Ltd.) were dissolved in 125.0 g of
anhydrous dimethylformamide (DMF; produced by Wako Pure Chemical
Industries Ltd.). After having nitrogen flow in this solution for 1
hour, 1 mL of DMF solution of 36 mg of 2,2'-azobisisobutyronitrile
(AIBIN; produced by Wako Pure Chemical Industries, Ltd.) was added
to the solution, and the solution was allowed to polymerize at
80.degree. C. for 8 hours. After completion of the polymerization,
100 mL of acetone (produced by Kokusan Chemical Co., Ltd.) was
added with stirring to the solution, then, the solution was added
dropwise to n-hexane (produced by Kokusan Chemical Co., Ltd.) to
form precipitates and the product was isolated. The isolated
product was dissolved in acetone and the resulting solution was
added dropwise to n-hexane to form precipitates and thus purified
totally three times. The purified product was dried under reduced
pressure over a whole day to obtain a surface treating agent. The
composition (molar ratio of monomer components) of the obtained
polymer was determined by .sup.1H-NMR. The molar ratio of monomers
was DMAA/DMAEMA/HEMA=67/28/5. The mass average molecular weight was
43,000.
Comparative Example 5
[0086] 1.5 g of N,N-diethyaminoethyl methacrylate (DEAEMA; produced
by Wako Pure Chemical Industries, Ltd.) and 20.0 g of
2-hydroxyethyl methacrylate (HEMA; produced by Wako Pure Chemical
Industries, Ltd.) were dissolved in 80.0 g of anhydrous
dimethylformamide (DMF; produced by Wako Pure Chemical Industries
Ltd.). After having nitrogen flow in this solution for 1 hour, 1 mL
of DMF solution of 22 mg of 2,2'-azobisisobutyronitrile (AIBIN;
produced by Wako Pure Chemical Industries, Ltd.) was added to the
solution, and the solution was allowed to polymerize at 80.degree.
C. for 8 hours. After completion of the polymerization, 60 mL of
acetone (produced by Kokusan Chemical Co., Ltd.) was added with
stirring to the solution, then, the solution was added dropwise to
n-hexane (produced by Kokusan Chemical Co., Ltd.) to form
precipitates and the product was isolated. The isolated product was
dissolved in acetone and the resulting solution was added dropwise
to n-hexane to form precipitates and thus purified totally three
times. The purified product was dried under reduced pressure over a
whole day to obtain a surface treating agent. The composition
(molar ratio of monomer components) of the obtained polymer was
determined by .sup.1H-NMR. The molar ratio of monomers was
DEAEMA/HEMA=5/95. The mass average molecular weight was 66,000.
(2) Evaluation of Performance of Various Surface Treating
Agents
Test Example 1
Amount of Fixation of Various Surface Treating Agents (Except
Example 8)
[0087] Preparation of GMA-grafted PU membrane
[0088] 21 cm.times.25 cm of a polyurethane sponge-like porous
membrane that is as thick as 1.2 mm (PU: E394 POTA, produced by
Nippon Miractran Co., Ltd.; mean pore diameter: 5.0 .mu.m,
porosity: 85%) was exposed for 30 seconds to plasma of argon flux
of 25 Pa with an output of 200 W. Then, the pressure of argon flow
was decreased to 0.5 Pa. After decreasing the argon pressure,
previously deaerated glycidyl methacrylate (GMA; produced by Wako
Pure Chemical Industries, Ltd.) was introduced under a negative
pressure and was graft polymerized at 56 Pa for 3 minutes. Residual
GMA monomer in the reaction system was evacuated with a vacuum pomp
for 3 minutes. Then, the system was returned to the atmospheric
pressure, and thus GMA-grafted PU membrane was obtained.
[0089] Fixation of the Surface Treating Agents
[0090] Using each of the solvents indicated in Table 1, 450 g of a
solution was prepared in 500 mL beaker, which contained a final
concentration of 0.5 mass % of each of the surface treating agents
synthesized in Examples 1 to 6 and Comparative Examples 1 to 5 and
a final concentration of 0.25 mass % of pyridine (produced by Wako
Pure Chemical Industries, Ltd.). 450 g of a solution was prepared
in 500 mL beaker, which contained a final concentration of 0.5 mass
% of the surface treating agent of Example 7 without adding
pyridine into a mixed solution of water and methanol where
methanol/water=1/1 (by mass ratio).
[0091] Into each of the solutions of the above surface treating
agents, the GMA-grafted membranes, in order to be immersed
completely in the solutions in 500 mL beaker, were cut into 3
sheets of 7 cm.times.25 cm respectively. And all the 3 sheets were
placed into each of the beakers and were synthesized by stirring in
constant temperature water bath at 65.degree. C. for 8 hours. Thus,
the various surface treating agents (except Example 8) were fixed
to the grafted membranes.
[0092] Washing of the Membranes Fixed with the Surface Treating
Agents
[0093] One sheet out of 3 sheets of the membranes fixed with the
various surface treating agents was dried continuously in the same
draft chamber after the fixation and further heated in an oven at
80.degree. C. for 8 hours. Each of the other 2 sheets was washed by
showering with RO water at 60.degree. C. for 8 hours, and was
washed by Soxhlet extraction-washing with methanol as solvent for 8
hours. Then, the washed sheet was dried in a draft chamber
overnight and further dried in an oven at 80.degree. C. for 4
hours.
[0094] Amount of Fixation of Unwashed or Washed Samples
[0095] The dried membranes fixed with the various surface treating
agents were investigated by Trypan Blue staining method. That is,
the resulting membranes were punched to obtain disks of .PHI. 26 mm
in diameter. Then, the disk was mounted in a holder made of PP
(produced by Advantech Co., Ltd.). The holder was filled with RO
water. Here, a concentration-adjusted of aqueous solution of Trypan
Blue (produced by Merck KGaA) was prepared to be absorbed in the
range of 1.15.+-.0.05 at the maximum absorption wavelength. The
concentration-adjusted aqueous solution of Trypan Blue was fed at
15 mL/min for 90 seconds. After the feeding, 50 mL of RO water was
fed to wash excessive Trypan Blue. The membrane was taken out of
the holder and was dried in an oven at 80.degree. C. Then, the
reflection absorption of 599 nm was measured using Chromatoscanner
CS-930 (producted by Shimadzu Corporation). The results obtained
are shown in Table 1.
Test Example 2
Amount of Fixation of Surface Treating Agent of Example 8
[0096] Preparation of AA-grafted PU membrane
[0097] 21 cm.times.25 cm of a polyurethane sponge-like porous
membrane that is as thick as 1.2 mm (PU: E394 POTA, produced by
Nippon Miractran Co., Ltd.; mean pore diameter: 5.0 .mu.m,
porosity: 85%) was exposed for 30 seconds to plasma of argon flux
of 25 Pa with an output of 200 W. Then, the pressure of argon flow
was decreased to 0.5 Pa. After decreasing the argon pressure,
previously deaerated acrylic acid (AA; produced by Wako Pure
Chemical Industries, Ltd.) was introduced under negative pressure
and was graft polymerized at 37 Pa for 5 minutes. Residual AA
monomer in the reaction system was evacuated with a vacuum pomp for
3 minutes. Then, the system was returned to atmospheric pressure,
and thus AA-grafted PU membrane was obtained.
[0098] Fixation of the Surface Treating Agent
[0099] 450 mL of an aqueous solution was prepared, which contained
each of final concentrations of 10 mM of ethylenediamine (EDA:
produced by Wako Pure Chemical Industries, Ltd.) and
dehydration-condensation agent DMT-MM (produced by Kokusan Chemical
Co., Ltd.) respectively. The solution was poured gently into 500 mL
beaker in which the AA-grafted membrane that was cut into 3 sheets
of 7 cm.times.25 cm was placed. And the sheets were reacted at room
temperature for 6 hours continuously in the same beaker. After
completion of the reaction, the membrane was washed by RO water for
3 hours, and was dried in an oven at 80.degree. C. for 4 hours. The
solution of the surface treating agent of Example 8 was prepared in
a mixed solution of water and methanol where methanol/water=1/1 (by
mass ratio) to a final concentration of 0.5 mass %. The solution
was prepared in 500 mL beaker to obtain 450 g. The 3 sheets of
surface aminationed AA-grafted membranes were placed into the
beaker and were stirred in constant temperature water bath at
65.degree. C. for 8 hours. Thus, the surface treating agent of
Example 8 was fixed to the grafted membrane.
[0100] Washing of the Membranes Fixed with the Surface Treating
Agent
[0101] Samples were prepared in the same manner as in Test Example
1.
[0102] Amount of Fixation of Unwashed or Washed Samples
[0103] Samples were prepared in the same manner as in Test Example
1. The results obtained are shown in Table 1.
TABLE-US-00001 TABLE 1 Solvent for Amount of fixation Composition
of surface treating agent fixation washed by washed by surface
treating agent (mol %) (by mass rtio) unwashed RO water methanol
Example 1 MEA/DMAEMA/HEMA = 90/5/5 water/methanol = 0.48 0.40 0.35
1/1 Example 2 DMAA/DMAEMA/HEMA = 92/3/5 water 0.40 0.32 0.32
Example 3 MEA/DEAEMA/HEMA = 98/1/1 water/methanol = 0.36 0.32 0.28
1/1 Example 4 DMAA/DMAPMAm/HEMA = 70/15/15 water 0.60 0.52 0.51
Example 5 EEMA/DMAEMA/HEMA = 76/12/12 water/methanol = 0.52 0.50
0.47 1/1 Example 6 MEA/DiPAEMA/HEMA = 87/10/3 water/methanol = 0.49
0.43 0.40 1/1 Example 7 MEA/DMAEA/AEAAm = 90/5/5 water/methanol =
0.47 0.40 0.38 1/1 Example 8 DMAA/DMAEMA/GMA = 90/5/5
water/methanol = 0.36 0.28 0.26 1/1 Comparative Example 1
MEA/DMAEMA = 95/5 water/methanol = 0.51 0.42 0.03 1/1 Comparative
Example 2 DMAA/DMAEMA = 95/5 water 0.49 0.02 0.00 Comparative
Example 3 MEA/HEMA = 95/5 water/methanol = 0.00 0.00 0.00 1/1
Comparative Example 4 DMAA/DMAEMA/HEMA = 67/28/5 water 0.87 0.75
0.72 Comparative Example 5 DEAEMA/HEMA = 5/95 water/methanol = 0.55
0.46 0.45 1/1
[0104] From Table 1, with respect to such polyurethane sponge-like
porous membranes (PU porous membranes) treated with the surface
treating agents which were obtained in Examples 1 to 8 and
Comparative Examples 4 and 5, that includes a monomer (B) having a
basic functional group and a monomer (C) having a reactive
functional group at the same time, it is apparent that the
membranes were strongly stained by Trypan Blue even after the RO
water-washing or the Soxhlet extraction-washing with methanol as
solvent. It showed that the surface treating agents having a basic
functional group were fixed on the PU porous membranes. On the
other hand, with respect to such PU porous membranes treated with
the surface treating agents which were obtained in Comparative
Examples 1 and 2, that includes monomer (B) having a basic
functional group but no monomer (C) having a reactive functional
group, and the surface treating agents which were obtained in
Comparative Example 3 that includes no monomer (B), it is shown
that the surface treating agents were washed away from the
membranes, using solvents that solve the surface treating agents.
The membranes were hardly stained or not stained at all by Trypan
Blue.
Test Example 3
Blood Filtration Property of Surface Treating Agents Fixed to PU
Sponge-Like Porous Membrane
[0105] In Test Example 1, the PU porous membranes Soxhlet
extraction-washed with methanol of Examples 1 to 8 and Comparative
Examples 3 to 5, and the unwashed PU porous membranes of
Comparative Examples 1 and 2 were punched to obtain disks of .PHI.
26 mm in diameter. The obtained one disk was assembled into a blood
circuit which was used as a sample of blood filtration property
test. Blood collected from healthy volunteers as whole blood with
CPD which was stored at 22.degree. C. for 24 hours was used. Each
of the samples was filtrated in an amount of 45 mL. Further,
expressed as Comparative Example 6, an untreated PU porous membrane
to which the surface treating agent was not fixed was also
subjected to the filtration and evaluated in the same manner.
Concentration of leucocytes and concentration of platelets before
and after filtration were calculated using automatic blood cell
counter (Sysmex XE2100, produced by Toa Medical Electronics (Sysmex
Corporation)). Leukocyte removal rate and platelet collection ratio
was calculated respectively according to the following equation.
The results obtained are shown in Table 2.
Leukocyte removal ratio (%)=(1-(number of leukocytes after
filtration)/(number of leukocytes before filtration))*100
Platelet collection ratio (%)=((number of platelets after
filtration)/(number of platelets before filtration))*100
TABLE-US-00002 TABLE 2 Leukocyte Platelet Composition of surface
treating agent removal collection surface treating agent (mol %)
ratio (%) ratio (%) note Example 1 MEA/DMAEMA/HEMA = 90/5/5 94.8
95.8 Soxhlet extraction-washed Example 2 DMAA/DMAEMA/HEMA = 92/3/5
95.3 95.6 Soxhlet extraction-washed Example 3 MEA/DEAEMA/HEMA =
98/1/1 93.3 96.2 Soxhlet extraction-washed Example 4
DMAA/DMAPMAm/HEMA = 70/15/15 97.2 94.8 Soxhlet extraction-washed
Example 5 EEMA/DMAEMA/HEMA = 76/12/12 95.2 94.9 Soxhlet
extraction-washed Example 6 MEA/DiPAEMA/HEMA = 87/10/3 96.6 95.0
Soxhlet extraction-washed Example 7 MEA/DMAEA/AEAAm = 90/5/5 94.4
95.3 Soxhlet extraction-washed Example 8 DMAA/DMAEMA/GMA = 90/5/5
93.3 95.1 Soxhlet extraction-washed Comparative Example 1
MEA/DMAEMA = 95/5 89.9 95.7 Unwashed Comparative Example 2
DMAA/DMAEMA = 95/5 70.2 95.2 Unwashed Comparative Example 3
MEA/HEMA = 95/5 60.3 97.0 Soxhlet extraction-washed Comparative
Example 4 DMAA/DMAEMA/HEMA = 67/28/5 99.8 20.2 Soxhlet
extraction-washed Comparative Example 5 DEAEMA/HEMA = 5/95 73.1
78.9 Soxhlet extraction-washed Comparative Example 6 Untreated PU
porous membrane 65.9 95.1 Unwashed
[0106] From Table 2, it is apparent that the PU porous membranes
fixed with the surface treating agents obtained in Examples 1 to 8
showed a tremendously improvement in leukocyte removal ratio with a
preservation of platelet collection ratio in comparison to the PU
porous membranes fixed with the surface treating agents obtained in
Comparative Examples 1 to 5 and untreated PU porous membrane of
Comparative Example 6. On the other hand, the PU porous membranes
treated with the surface treating agents obtained in Comparative
Examples 1 and 2 which cannot be fixed to the membranes, showed a
poorer leukocyte removal ratio in comparison to any of Examples 1
to 8, probably because the surface treating agents were washed away
into blood. Further, the surface treating agents obtained in
Comparative Example 3 lowered the leukocyte removal ratio in
comparison to the untreated membrane (Comparative Example 6). The
surface treating agents obtained in Comparative Example 4 having a
lot of basic functional groups gave a big decrease in the leukocyte
removal ratio in comparison to the untreated membrane. While, in
Comparative Example 5, an improved leukocyte removal ratio was
obtained in comparison to the untreated membrane but the leukocyte
removal ratio fell short of any surface treating agent of Examples
1 to 8, further the platelet collection ratio was apparently
decreased.
Test Example 4
Blood Filtration Property of Surface Treating Agents Fixed to
Nonwoven Fabric of Polyester
[0107] The same procedures were repeated as in Example 1 except
that nonwoven fabrics of polypropylene (PP nonwoven fabrics) having
an average fiber diameter of 2.1 .mu.m, a basis weight of 31
g/m.sup.2 and a thickness of 0.20 mm were used. That is, the
surface treating agents of Examples 1 and 2 were fixed to the
fabrics, and the fabrics were Soxhlet extraction-washed with
methanol. Thus, PP nonwoven fabrics fixed with two kinds of surface
treating agents were obtained. Each of the PP nonwoven fabrics
fixed with the surface treating agents were punched to obtain disks
of .PHI. 26 mm in diameter. The obtained 6 disks were assembled
into a blood circuit which was used as a sample of blood filtration
property test. Further, expressed as Comparative Example 7, a PP
nonwoven fabrics to which the surface treating agent was not fixed
at all and expressed as Comparative Example 8, a PP nonwoven fabric
onto which 0.2% of Decaglyn (a surfactant: produced by Nikko
Chemicals Co., Ltd.) was simply coated were also assembled into a
blood circuit each of which was used as a sample of blood
filtration property test in the same manner. The same procedures
were repeated as in Test Example 3. That is, blood collected from
healthy volunteers as whole blood with CPD which was stored at
22.degree. C. for 24 hours was used. Each of the samples was
filtrated in an amount of 45 mL. Leukocyte removal rate and
platelet collection ratio was calculated respectively. The results
obtained are shown in Table 3.
TABLE-US-00003 TABLE 3 Leukocyte Platelet Composition of surface
treating agent removal collection surface treating agent (mol %)
ratio (%) ratio (%) note Example 1 MEA/DMAEMA/HEMA = 90/5/5 92.7
91.9 Example 2 DMAA/DMAEMA/HEMA = 92/3/5 91.4 92.8 Comparative
Example 7 Untreated PP nonwoven fabric -- -- not infiltrated
Comparative Example 8 Surfactant coated PP nonwoven fabric 60.0
67.7
[0108] From Table 3, it is apparent that with regard to untreated
PP nonwoven fabric in Comparative Example 7, blood could not be
infiltrated into the fabric and hence blood could not be filtered,
while, the PP nonwoven fabric fixed with the surface treating
agents obtained in Examples 1 and 2 not only showed an improved
hydrophilicity and enabled filtration, but also showed a great
improvement in leukocyte removal ratio and platelet collection
ratio in comparison to the surfactant coated PP nonwoven fabric in
Comparative Example 8.
Test Example 5
Blood Filtration Property of Mockup Configuration
[0109] A punched disk of .PHI. 30 mm in diameter of untreated PU
porous membrane having mean pore diameter of 6.0 .mu.m for
pre-filter unit, two disks of membrane having mean pore diameter of
4.0 .mu.m for main filter unit and a disk of membrane (mean pore
diameter of 5.0 .mu.m) fixed with the surface treating agent of
Example 1, 4 disks in total were assembled into a filtration module
in this order which was used as a mockup configurational
sample.
[0110] Blood filtration evaluation was carried out using blood
collected from healthy volunteers as whole blood with CPD which was
stored at 22.degree. C. for 1 hour was filtrated in an amount of 60
mL. In this blood filtration evaluation blood was filtered made to
pass from the untreated membrane side. Concentrations of platelets
and concentrations of erythrocytes before and after filtration were
calculated respectively using automatic blood cell counter (Sysmex
XE2100, produced by Toa Medical Electronics (Sysmex Corporation)).
Leaked leukocyte number was calculated using flowcytometer (EPICS
XL; producted by Beckman Coulter, Inc.). The results obtained are
shown in Table 4.
[0111] In addition, instead of the membrane fixed with the surface
treating agent of Example 1, a disk of membrane fixed with the
surface treating agent of Example 2 was assembled into the
filtration module made of 4 disks in total, the same evaluation
procedures were repeated as above-mentioned. The results obtained
are shown in Table 4.
[0112] Further, expressed as Comparative Example 9, instead of the
membrane fixed with the surface treating agent of Example 1, a disk
of membrane having mean pore diameter of 5.0 .mu.m without the
surface treating agent fixed was assembled into the filtration
module made of 4 disks in total, the same evaluation procedures
were repeated as above-mentioned. Furthermore, expressed as
Comparative Example 10, instead of the membrane fixed with the
surface treating agent of Example 1, 4 disks of membranes having
mean pore diameter of 4.0 .mu.m were assembled into the filtration
module made of 6 disks in total, the same evaluation procedures
were repeated as above-mentioned. The results obtained are shown in
Table 4.
TABLE-US-00004 TABLE 4 Leaked Leukocyte Platelet Erythrocyte number
collection collection surface treating agent Structure of membrane
(cell/unit) ratio (%) ratio (%) Example 1 Pre-filter unit: 1 disk
of membrane having mean 1.7*10.sup.4 90.2 95.4 pore diameter
(untreated) of 6 .mu.m Main filter unit (Up-stream): 2 disks of
membranes having mean pore diameter of 4 .mu.m (untreated) Main
filter unit (Down-stream): 1 disk of membrane having mean pore
diameter of 5 .mu.m (MEA/DMAEMA/HEMA = 90/5/5 treated) Example 2
Pre-filter unit: 1 disk of membrane having mean 2.0*10.sup.4 91.1
95.8 pore diameter of 6 .mu.m (untreated) Main filter unit
(Up-stream): 2 disks of membranes having mean pore diameter of 4
.mu.m (untreated) Main filter unit (Down-stream): 1 disk of
membrane having mean pore diameter of 5 .mu.m (DMAA/DMAEMA/HEMA =
92/3/5 treated) Comparative Example 9 Pre-filter unit: 1 disk of
membrane having mean 2.6*10.sup.6 90.6 95.2 pore diameter of 6
.mu.m (untreated) Main filter unit (Up-stream): 2 disks of
membranes having mean pore diameter of 4 .mu.m (untreated) Main
filter unit (Down-stream): 1 disk of membrane having mean pore
diameter of 5 .mu.m (untreated) Comparative Example 10 Pre-filter
unit: 1 disk of membrane having mean 4.2*10.sup.4 78.7 91.8 pore
diameter of 6 .mu.m (untreated) Main filter unit (Up-stream): 2
disks of membranes having mean pore diameter of 4 .mu.m (untreated)
Main filter unit (Down-stream): 4 disks of membranes having mean
pore diameter of 4 .mu.m (untreated)
[0113] As is obvious from Table 4, when increasing a number of
disks (Comparative Example 10) to improve leukocyte removal ratio,
it increases the amount of residual platelets and erythrocytes in
the filtering material, the platelet collection rate and the
erythrocyte collection rate decrease; in contrast, by assembling
the membrane fixed with the surface treating agents of the present
invention (Examples 1 and 2) which have excellent leukocyte
adsorbability and enables a smaller number of disks to improve
leukocyte removal ratio tremendously. Thus, a leukocyte removing
filter having an improved platelet collection property can be
provided.
Test Example 6
Evaluation of Antithrombotic Performance of Surface Treating
Agents
[0114] Under the same condition instead of the PU porous membranes
of Examples 1 and 2, 0.1 mm thickness of polyurethane sheets (PU:
E394 POTA, produced by Nippon Miractran Co., Ltd.) was used, the
sheets were fixed with the surface treating agents of Examples 1 to
8 and Comparative Examples 1 to 5. Each of the fixed sheets was
washed by Soxhlet extraction-washing with methanol as solvent for 8
hours. And then, each sheet was dried in an oven at 80.degree. C.
for 4 hours. Thus, expressed as Comparative Example 11, an
untreated PU sheet to which the surface treating agent was not
fixed was prepared.
[0115] Under the same condition instead of the PU sheet, 0.1 mm
thickness of polypropylene sheet (PP: produced by Sumitomo Chemical
Co., Ltd.) and polyethylene terephthalate sheet (PET: produced by
Teijin DuPont Films Japan Limited) were used, the sheets were
fixed, washed and dried. Further, expressed as Comparative Examples
12 and 13, an untreated PP sheet and an untreated PET sheet to
which the surface treating agent was not fixed were prepared.
[0116] The prepared sheets fixed with each surface treating agents
and untreated sheets were subjected to platelet adhesion tests as
follows. First, 50 mL of whole blood was collected into a blood
collecting tube in which 7 mL of CPD liquid had been put. The blood
in the tube was centrifuged at 1,200 rpm for 5 minutes to separate
PRP (platelet rich plasma). After fractionating a portion of PRP,
the remainder was further centrifuged at 3,000 rpm for another 10
minutes to obtain PPP (platelet poor plasma). Then, the
first-fractionated PRP was diluted with PPP to adjust the number of
platelet to 1*10.sup.5 cell/.mu.L. 0.2 mL of diluted PRP was added
gently dropwise on each sample. After leaving them to stand at room
temperature for 30 minutes, the samples were rinsed twice with PSS
(physiological saline solution). Then, the samples were immersed in
1 mass % PSS solution of glutaraldehyde and kept at room
temperature for 1 hour. After the rinsing and drying, the samples
were ion sputtered, and then observed on SEM (JEOL JSM-840) with
taking photographs (1,000 times magnified, 5 views).
[0117] With changing blood samples, this procedure using fresh
blood sample was repeated 3 times in total the platelet adhesion
tests were subjected. The obtained mean platelet adhesion numbers
are shown in Table 5 (PU sheet), Table 6 (PP sheet) and Table 7
(PET sheet) respectively. With respect to the morphology of
platelet: the platelet that retained round shape was named "Type
I", the platelet that had some pseudopods was named "Type II" and
the platelet that extended lost the original shape was named "Type
III".
TABLE-US-00005 TABLE 5 (PU sheet) platelet adhesion numbers
Composition of surface treating agent (cell/8.5*10.sup.-3 mm.sup.2)
surface treating agent (mol %) Type I Type II Type III Total
Example 1 MEA/DMAEMA/HEMA = 90/5/5 4.1 1.0 0.1 5.2 Example 2
DMAA/DMAEMA/HEMA = 92/3/5 2.7 0.8 0.4 3.9 Example 3 MEA/DEAEMA/HEMA
= 98/1/1 1.3 1.1 0.6 3.0 Example 4 DMAA/DMAPMAm/HEMA = 70/15/15 4.2
3.1 1.8 9.1 Example 5 EEMA/DMAEMA/HEMA = 76/12/12 3.7 2.4 1.2 7.3
Example 6 MEA/DiPAEMA/HEMA = 87/10/3 2.9 1.7 0.4 5.0 Example 7
MEA/DMAEA/AEAAm = 90/5/5 2.2 1.3 0.7 4.2 Example 8 DMAA/DMAEMA/GMA
= 90/5/5 3.9 1.6 0.8 6.3 Comparative Example 1 MEA/DMAEMA = 95/5
10.3 19.6 31.5 61.4 Comparative Example 2 DMAA/DMAEMA = 95/5 13.8
20.1 34.4 68.3 Comparative Example 3 MEA/HEMA = 95/5 16.5 10.9 0.4
27.8 Comparative Example 4 DMAA/DMAEMA/HEMA = 67/28/5 15.4 108.1
211.8 335.3 Comparative Example 5 DEAEMA/HEMA = 5/95 20.9 19.6 79.1
119.6 Comparative Example 11 Untreated PU porous membrane 12.6 18.7
33.7 65.0
TABLE-US-00006 TABLE 6 (PP sheet) platelet adhesion numbers
Composition of surface treating agent (cell/8.5*10.sup.-3 mm.sup.2)
surface treating agent (mol %) Type I Type II Type III Total
Example 1 MEA/DMAEMA/HEMA = 90/5/5 5.8 1.9 0.5 8.2 Example 2
DMAA/DMAEMA/HEMA = 92/3/5 4.9 1.8 0.7 7.4 Example 3 MEA/DEAEMA/HEMA
= 98/1/1 3.9 1.4 0.4 5.7 Example 4 DMAA/DMAPMAm/HEMA = 70/15/15 6.6
2.7 0.9 10.2 Example 5 EEMA/DMAEMA/HEMA = 76/12/12 6.1 2.1 1.3 9.5
Example 6 MEA/DiPAEMA/HEMA = 87/10/3 6.8 1.6 1.1 9.5 Example 7
MEA/DMAEA/AEAAm = 90/5/5 4.4 0.9 0.6 5.9 Example 8 DMAA/DMAEMA/GMA
= 90/5/5 5.3 1.3 1.6 8.2 Comparative Example 1 MEA/DMAEMA = 95/5
6.3 11.9 673.7 691.9 Comparative Example 2 DMAA/DMAEMA = 95/5 2.1
0.2 721.5 723.8 Comparative Example 3 MEA/HEMA = 95/5 21.1 17.1 0.8
39.0 Comparative Example 4 DMAA/DMAEMA/HEMA = 67/28/5 4.0 89.9
281.9 375.8 Comparative Example 5 DEAEMA/HEMA = 5/95 10.9 28.9 88.1
127.9 Comparative Example 12 Untreated PP porous membrane 0.7 1.2
711.3 713.2
TABLE-US-00007 TABLE 7 (PET sheet) platelet adhesion numbers
Composition of surface treating agent (cell/8.5*10.sup.-3 mm.sup.2)
surface treating agent (mol %) Type I Type II Type III Total
Example 1 MEA/DMAEMA/HEMA = 90/5/5 6.5 2.1 0.1 8.7 Example 2
DMAA/DMAEMA/HEMA = 92/3/5 6.2 0.8 0.3 7.3 Example 3 MEA/DEAEMA/HEMA
= 98/1/1 6.2 1.8 0.1 8.1 Example 4 DMAA/DMAPMAm/HEMA = 70/15/15 5.9
2.6 1.2 9.7 Example 5 EEMA/DMAEMA/HEMA = 76/12/12 6.9 2.3 0.9 10.1
Example 6 MEA/DiPAEMA/HEMA = 87/10/3 7.2 3.4 1.6 12.2 Example 7
MEA/DMAEA/AEAAm = 90/5/5 7.8 2.1 0.2 10.1 Example 8 DMAA/DMAEMA/GMA
= 90/5/5 6.2 1.2 0.5 7.9 Comparative Example 1 MEA/DMAEMA = 95/5
1.2 4.9 592.2 598.3 Comparative Example 2 DMAA/DMAEMA = 95/5 0.2
1.9 639.1 641.2 Comparative Example 3 MEA/HEMA = 95/5 18.9 10.8 0.2
29.9 Comparative Example 4 DMAA/DMAEMA/HEMA = 67/28/5 16.1 124.2
189.3 329.6 Comparative Example 5 DEAEMA/HEMA = 5/95 19.0 26.3 65.0
110.3 Comparative Example 13 Untreated PET porous membrane 0.2 2.7
648.3 651.2
[0118] As is obvious from Tables 5 to 7, the PU, PP and PET sheets
treated with the surface treating agents obtained in Examples 1 to
8 inhibited platelet adhesion better than the sheets treated with
the surface treating agents of Comparative Examples 1 to 5 and the
untreated sheets of Comparative Examples 11 to 13. Further, most of
the adhered platelets retained round shape in the sheets of the
present invention.
Test Example 7
Fixation to Stainless Plate
[0119] Stainless plates of 0.5 mm thickness and of 25 mm.times.50
mm were immersed in 0.1 mass % toluene (produced by Wako Pure
Chemical Industries, Ltd.) solution of
3-glycidoxypropyltrimethoxysilane (KBM-403: produced by Shin-Etsu
Chemical Co., Ltd.) overnight. Then the obtained plates were washed
by toluene to rinse excessive 3-glycidoxypropyltrimethoxysilane.
The washed plates were heated in an oven at 80.degree. C. for 4
hours. Thus, stainless plates treated with the silane coupling
agent were obtained.
[0120] In the same manner as in Test Example 1, the plates were
fixed with the surface treating agents of Examples 1 to 5
respectively except that stainless plates treated with the silane
coupling agent were used instead of the GMA-grafted PU porous
membranes. The stainless plates fixed with the surface treating
agents were washed by Soxhlet extraction-washing with methanol for
8 hours. The washed plates were observed on an X-ray optoelectronic
spectrophotometer (JPS-905X, produced by JEOL Ltd.) to examine if
iron atoms are present on the surface of the plates. As a result,
no peak attributable to iron atom was observed in the plates. That
is, it is confirmed that each of the plates are coated completely
and fixed with the surface treating agent of each of the
Examples.
DESCRIPTION OF REFERENCE NUMERALS
[0121] 1 Blood treatment filter [0122] 2 Housing [0123] 3 Cover
[0124] 4 Blood inlet port [0125] 5 Bottom [0126] 6 Blood outlet
port [0127] 7 Filter unit [0128] 8 Blood inlet chamber [0129] 9
Blood outlet chamber
* * * * *